Paclitaxel/Carboplatin With or Without Cetuximab in CUP

Summary

The purpose of this study is to determine whether an addition of cetuximab to carboplatin/paclitaxel can improve efficacy in comparison to carboplatin/paclitaxel in patients with carcinoma of unknown-primary.

Timeline

Start

2009-07

Primary completion

2010-07

Completion

2011-08

Outcome

Missed primary endpoint

paper There was no significant difference in PFS (3.7 vs 4.6 months, HR 0.98) or OS (8.1 vs 7.4, HR 1.1) between the two treatment groups. PMID 33235314 ↗

paper Cetuximab plus paclitaxel/carboplatin did not improve PFS, OS and RR in metastatic CUP compared to paclitaxel/carboplatin alone. PMID 33235314 ↗

Publications

• Folprecht G, Trautmann K, Stein A, Huebner G, Stahl M, Kasper S, Kretzschmar A, Kohne CH, Grunwald V, Hofheinz RD, Schutte K, Loffler H, Bokemeyer C, Kramer A; Arbeitsgemeinschaft Internistische Onkologie (AIO) - CUP Group. Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP. Br J Cancer. 2021 Feb;124(4):721-727. doi: 10.1038/s41416-020-01141-8. Epub 2020 Nov 25.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cetuximab	Monoclonal antibody	250 mg/m2	—
Background	Carboplatin	Small molecule	—	—
Background	Paclitaxel	Small molecule	175 mg/m2	—

Indications